Date: 2011-10-31
Type of information: R&D agreement
Compound: gene therapy using LentiVector® gene delivery technology expressing a COX-2 gene and a PGF-2alpha receptor gene
Company: Oxford BioMedica (UK) Mayo Clinic (USA)
Therapeutic area: Ophtalmologic diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: Oxford BioMedica has entered into a research and development collaboration with Mayo Clinic, Rochester (USA) to develop a novel gene therapy for the treatment of chronic glaucoma. Under the terms of the agreement, Mayo Clinic and Oxford BioMedica will undertake pre-clinical studies to establish the feasibility of treating glaucoma using Oxford BioMedica's proprietary LentiVector® gene delivery technology expressing a COX-2 gene and a PGF-2alpha receptor gene in order to reduce intraocular pressure. The collaboration includes an option for exclusive US rights to license Mayo Clinic's glaucoma technology, which Oxford BioMedica can exercise upon completion of pre-clinical studies under confidential terms agreed by Mayo Clinic and the Company. The collaboration builds on earlier pre-clinical research, conducted by Eric Poeschla M.D., Mayo Clinic and his research team, which has established initial proof-of-concept for this approach to treating chronic glaucoma. This work will be extended using the LentiVector® technology and may support the rapid transition of another novel ocular gene therapy into clinical development.
Financial terms: Financial details were not disclosed.
Latest news:
